Last updated: June 19, 2026
Executive summary
No reliable, citable public information is available to confirm that “DECA-DURABOLIN” is a distinct, FDA-reviewed drug product with an identifiable active ingredient, sponsor, clinical trial registry entries, marketing authorization status, or revenue baseline. Without those anchor facts, a complete clinical-trials update, Orange Book status, patent/ exclusivity timeline, and market projection cannot be produced without fabrication.
What clinical trials exist for DECA-DURABOLIN, and what are the latest results?
Answer: No verifiable, citable clinical trial record can be provided for “DECA-DURABOLIN” as a uniquely identified drug entity based on the available information.
Which trial registries should show DECA-DURABOLIN studies?
- ClinicalTrials.gov
- EU Clinical Trials Register
- WHO ICTRP
- Published literature in PubMed
What endpoints are typically reported for anabolic steroid products?
- Serum testosterone/IGF-1 changes
- Lean body mass and strength outcomes
- Safety: hematocrit, lipid profile, liver enzymes, BP, PSA (if applicable)
What is the DECA-DURABOLIN FDA status and is it approved?
Answer: The FDA approval/marketing status of “DECA-DURABOLIN” cannot be validated to a specific NDA/ANDA/BLA record from the information provided.
How to locate FDA status for an identifiable product
- FDA “Drugs@FDA” label and approval history
- Orange Book for listed patents tied to an approved NDA
- REMS database (if applicable)
What FDA pathway would typically apply if approved?
- NDA (if brand)
- ANDA (if generic; would require an established reference listed drug)
- BLA would apply only for biologics, which “DECA-DURABOLIN” does not clearly establish from the provided topic text.
What patents protect DECA-DURABOLIN, and when do they expire?
Answer: Patent protection cannot be enumerated because the underlying reference product (NDA/Orange Book record) cannot be confirmed for “DECA-DURABOLIN.”
What to map in a full patent estate review
- Drug substance patents (active ingredient / ester)
- Formulation patents (dosage form, concentration, release profile)
- Method-of-use patents (indications, dosing regimens)
- Manufacturing/process patents (crystallization, purification, aseptic filling)
- Pediatric exclusivity and patent term adjustments
When does DECA-DURABOLIN lose exclusivity?
Answer: Exclusivity timelines cannot be computed because the product’s FDA approval date, exclusivity grants, and Orange Book listing cannot be identified.
Exclusivity mechanisms typically assessed
- 5-year New Chemical Entity (NCE)
- 3-year New Clinical Investigation (NCI)
- 6-month pediatric extension
- 7-year orphan drug (if applicable)
- Patent term adjustment effects
What generics or biosimilars are at risk for DECA-DURABOLIN?
Answer: Launch risk cannot be assessed without a confirmed reference listed drug and its relevant patent-expiration and exclusivity windows.
What Paragraph IV would require
- ANDA filed against a specific RLD with notified certification to Orange Book patents
- Litigation and settlement dates that tie back to the same patent list
What formulation patents apply to DECA-DURABOLIN (if it is an injectable or long-acting product)?
Answer: Formulation patent coverage cannot be specified for “DECA-DURABOLIN” without confirmed dosage form and Orange Book-linked patent numbers.
What “long-acting depot” products usually patent
- Ester composition and stability
- Vehicle system (oil composition, viscosity)
- Sterility assurance and fill-finish parameters
- Particle size or depot precipitation controls (if relevant)
Which companies manufacture or market DECA-DURABOLIN?
Answer: Manufacturer and marketer identities cannot be confirmed for “DECA-DURABOLIN” from the provided information, so a competitive landscape cannot be reliably constructed.
Competitive mapping approach (when product identity is confirmed)
- US: Orange Book RLD manufacturers and ANDA applicants
- EU: marketing authorization holders (EMA)
- Global: national regulator databases
- Labeler codes and NDC crosswalks (if applicable)
How does DECA-DURABOLIN compare with related anabolic steroid products?
Answer: Direct comparison cannot be made without confirming the active ingredient(s), ester/strength, dosing interval, and approved indications for “DECA-DURABOLIN.”
Typical comparison dimensions
- Active ingredient and ester form
- Dosing frequency and route (IM depot vs other)
- Approved indications and target populations
- Safety monitoring requirements and labeling warnings
What market size and revenue projection is possible for DECA-DURABOLIN?
Answer: A market projection cannot be produced without identifying:
- the active ingredient and approved scope
- current sales base (or a defensible proxy)
- geography of commercial availability
- payer coverage and pricing benchmarks
Key Takeaways
- A defensible clinical trials update, regulatory status check, patent/exclusivity timeline, and market projection for “DECA-DURABOLIN” cannot be completed because the product cannot be uniquely validated to a specific approved drug entity from the information provided.
- No patent estate, Orange Book status, Paragraph IV risk, or revenue forecast can be stated without risking inaccurate attribution.
FAQs
- How do I verify whether a branded name like DECA-DURABOLIN maps to an FDA Orange Book reference listed drug?
- What data fields are required to build a full exclusivity timeline for an approved injectable product?
- How are Paragraph IV certifications tied to specific Orange Book patent numbers for an ANDA?
- What endpoints are most consistently reported in clinical trials of long-acting anabolic steroid formulations?
- How should market projections for niche hormone therapies be modeled when approved indications and geography are unclear?
References
- FDA. Drugs@FDA (database).
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- ClinicalTrials.gov (database).
- EMA. European public assessment reports (EPAR) and human medicines.
- WHO ICTRP (database).
